MedTrace Logo

Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ET

NCT03071172 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 252

Last updated 2017-03-06

No results posted yet for this study

Summary

The aim of this study was to evaluate the efficacy and safety of domestic recombinant human follicle stimulating hormone (rhFSH) stimulating ovarian to promote follicular development before assisted reproductive technology, which was non-inferiority than that of the imported rhFSH.

Conditions

  • Ovarian Hyperstimulation Syndrome

Interventions

DRUG

Triptorelin for Injection

Drugs for IVF-ET (in vitro fertilization and embryo transfer).

DRUG

Recombinant Human Choriogonadotropin alfa Solution for Injection

Drugs for IVF-ET (in vitro fertilization and embryo transfer).

DRUG

Progesterone Soft Capsules

Drugs for IVF-ET (in vitro fertilization and embryo transfer).

Sponsors & Collaborators

  • Peking University Third Hospital

    collaborator OTHER

  • The First Affiliated Hospital with Nanjing Medical University

    collaborator OTHER

  • Women's Hospital School Of Medicine Zhejiang University

    collaborator OTHER

  • Xiangya Hospital of Central South University

    collaborator OTHER

  • Sixth Affiliated Hospital, Sun Yat-sen University

    collaborator OTHER

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    collaborator OTHER

  • The First Affiliated Hospital of Anhui Medical University

    collaborator OTHER

  • Changchun GeneScience Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Rong Li, Doctor · Peking University Third Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-31
Primary Completion
2017-12-31
Completion
2018-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03071172 on ClinicalTrials.gov